Literature DB >> 10619821

House dust mite-induced airway changes in hu-SCID mice.

C Duez1, J Kips, J Pestel, K Tournoy, A B Tonnel, R Pauwels.   

Abstract

SCID (severe combined immunodeficiency) mice reconstituted with peripheral blood mononuclear cells (PBMC) from Dermatophagoides pteronissynus (Dpt)-sensitive patients and exposed to Dpt aerosol (allergic hu-SCID mice) develop human IgE and pulmonary inflammation. The present study investigated concomitant changes in airway hyperresponsiveness (AHR). No significant difference in baseline airway responsiveness was seen between nonreconstituted SCID mice exposed or not to Dpt aerosol at Day 35. Allergic hu-SCID mice developed AHR (provocative dose of carbachol causing a 50% increase in lung resistance [PD(50) RL] = 96.33 +/- 16.88 microg/kg) compared with nonallergic hu-SCID mice (PD(50) RL = 242.03 +/- 37.84 microg/kg) and nonreconstituted SCID mice (PD(50) RL = 297.60 +/- 45. 60 microg/kg) exposed to Dpt aerosol. An inverse correlation was observed between PD(50) RL (Day 35) and total human IgE at Day 7 (r = -0.58) and Day 15 (r = -0.64). However, no correlation existed between PD(50) RL and human cell number in the lungs of allergic hu-SCID mice. Moreover, despite the absence of eosinophils, the bronchoalveolar lavage fluid (BALF) of allergic hu-SCID mice had more human interleukin-5 (IL-5) (3.28 +/- 0.40 pg/ml, n = 13) than nonallergic hu-SCID mice (< 0.5 pg/ml) which inversely correlated with the PD(50) RL (r = -0.61). No tumor necrosis factor-alpha (TNF-alpha), IL-6, or IL-4 was detected. These observations indicate that humanized allergic hu-SCID mice may develop AHR after exposure to the relevant allergen, suggesting that this model may improve our understanding of AHR, one characteristic feature of allergic asthma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10619821     DOI: 10.1164/ajrccm.161.1.9806026

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  5 in total

1.  Antagonism of TIM-1 blocks the development of disease in a humanized mouse model of allergic asthma.

Authors:  Sanchaita Sriwal Sonar; Yen-Ming Hsu; Melanie Lynn Conrad; Gerard R Majeau; Ayse Kilic; Ellen Garber; Yan Gao; Chioma Nwankwo; Gundi Willer; Jan C Dudda; Hellen Kim; Véronique Bailly; Axel Pagenstecher; Paul D Rennert; Harald Renz
Journal:  J Clin Invest       Date:  2010-07-12       Impact factor: 14.808

2.  Mouse Models of Asthma: Characteristics, Limitations and Future Perspectives on Clinical Translation.

Authors:  Tolga Akkoc; Liam O'Mahony; Ruth Ferstl; Cezmi Akdis; Tunc Akkoc
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

Review 3.  THE JEREMIAH METZGER LECTURE NOVEL THERAPEUTIC STRATEGIES OF ALLERGIC AND IMMUNOLOGIC DISORDERS.

Authors:  Ronald G Crystal; Odelya E Pagovich
Journal:  Trans Am Clin Climatol Assoc       Date:  2018

4.  PD-1 pathway regulates ILC2 metabolism and PD-1 agonist treatment ameliorates airway hyperreactivity.

Authors:  Doumet Georges Helou; Pedram Shafiei-Jahani; Richard Lo; Emily Howard; Benjamin P Hurrell; Lauriane Galle-Treger; Jacob D Painter; Gavin Lewis; Pejman Soroosh; Arlene H Sharpe; Omid Akbari
Journal:  Nat Commun       Date:  2020-08-10       Impact factor: 14.919

Review 5.  Mimicking Antigen-Driven Asthma in Rodent Models-How Close Can We Get?

Authors:  Francesca Alessandrini; Stephanie Musiol; Evelyn Schneider; Frank Blanco-Pérez; Melanie Albrecht
Journal:  Front Immunol       Date:  2020-09-30       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.